{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T12:35:07Z","timestamp":1782995707859,"version":"3.54.5"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,27]]},"DOI":"10.7759\/cureus.79766","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T17:28:36Z","timestamp":1740677316000},"source":"Crossref","is-referenced-by-count":1,"title":["Sustained Virological Response After Direct-Acting Antiviral Therapy in Hepatitis C Virus-Infected Individuals With and Without Decompensated Liver Cirrhosis: A One-Year Follow-Up Study"],"prefix":"10.7759","author":[{"given":"Shailja","family":".","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Radera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit","family":"Rungta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amar","family":"Jeet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amita","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Hepatitis C. (2023). Accessed. January 14, 2025: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c#:~:text=For%20World%20Hepatitis%20Day%202023,the%202030%...."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.18410\/jebmh\/2019\/436","article-title":"Efficacy of directly acting antiviral drugs for HCV in real life: experience from a tertiary care centre of North India","volume":"5","author":"Kumar A","year":"2019","unstructured":"Kumar A, Kumar S, Deep A, et al.. Efficacy of directly acting antiviral drugs for HCV in real life: experience from a tertiary care centre of North India. J Evid Based Med Healthc. 2019, 5:2138-41. 10.18410\/jebmh\/2019\/436","journal-title":"J Evid Based Med Healthc"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2014.05.006","article-title":"Consensus statement of HCV task force of the Indian National Association for Study of the Liver (INASL). Part I: Status report of HCV infection in India","volume":"4","author":"Puri P","year":"2014","unstructured":"Puri P, Anand AC, Saraswat VA, et al.. Consensus statement of HCV task force of the Indian National Association for Study of the Liver (INASL). Part I: Status report of HCV infection in India. J Clin Exp Hepatol. 2014, 4:106-16. 10.1016\/j.jceh.2014.05.006","journal-title":"J Clin Exp Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis","volume":"373","author":"Curry MP","year":"2015","unstructured":"Curry MP, O'Leary JG, Bzowej N, et al.. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015, 373:2618-28. 10.1056\/NEJMoa1512614","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.05.010","article-title":"Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease","volume":"149","author":"Charlton M","year":"2015","unstructured":"Charlton M, Everson GT, Flamm SL, et al.. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015, 149:649-59. 10.1053\/j.gastro.2015.05.010","journal-title":"Gastroenterology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.4103\/ijmr.IJMR_679_15","article-title":"Newer direct-acting antivirals for hepatitis C virus infection: perspectives for India","volume":"146","author":"Gupta V","year":"2017","unstructured":"Gupta V, Kumar A, Sharma P, Arora A. Newer direct-acting antivirals for hepatitis C virus infection: perspectives for India. Indian J Med Res. 2017, 146:23-33. 10.4103\/ijmr.IJMR_679_15","journal-title":"Indian J Med Res"},{"key":"ref7","unstructured":"Diagnosis and management of viral hepatitis national guidelines for 2018. (2018). Accessed. January 14, 2025: https:\/\/nvhcp.mohfw.gov.in\/Guidelines."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ948","article-title":"Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis","volume":"62","author":"Simmons B","year":"2016","unstructured":"Simmons B, Saleem J, Hill A, Riley RD, Cooke GS. Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis. Clin Infect Dis. 2016, 62:683-94. 10.1093\/cid\/civ948","journal-title":"Clin Infect Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.04.038","article-title":"Magnitude and kinetics of decrease in liver stiffness after antiviral therapy in patients with chronic hepatitis C: a systematic review and meta-analysis","volume":"16","author":"Singh S","year":"2018","unstructured":"Singh S, Facciorusso A, Loomba R, Falck-Ytter YT. Magnitude and kinetics of decrease in liver stiffness after antiviral therapy in patients with chronic hepatitis C: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018, 16:27-38. 10.1016\/j.cgh.2017.04.038","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2022.00006","article-title":"Efficacy and safety of sofosbuvir-based regimens in hepatitis C patients with decompensated cirrhosis: a systematic review and meta-analysis","volume":"11","author":"Zhang W","year":"2023","unstructured":"Zhang W, Zhang J, Tang S, et al.. Efficacy and safety of sofosbuvir-based regimens in hepatitis C patients with decompensated cirrhosis: a systematic review and meta-analysis. J Clin Transl Hepatol. 2023, 11:144-55. 10.14218\/JCTH.2022.00006","journal-title":"J Clin Transl Hepatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/cells8040313","article-title":"SVR12 higher than 97% in GT3 cirrhotic patients with evidence of portal hypertension treated with SOF\/VEL without ribavirin: a nation-wide cohort study","volume":"8","author":"Mangia A","year":"2019","unstructured":"Mangia A, Cenderello G, Copetti M, et al.. SVR12 higher than 97% in GT3 cirrhotic patients with evidence of portal hypertension treated with SOF\/VEL without ribavirin: a nation-wide cohort study. Cells. 2019, 8:313. 10.3390\/cells8040313","journal-title":"Cells"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12091517","article-title":"Direct-acting antivirals for HCV treatment in decompensated liver cirrhosis patients: a systematic review and meta-analysis","volume":"12","author":"An J","year":"2022","unstructured":"An J, Park DA, Ko MJ, Ahn SB, Yoo JJ, Jun DW, Yim SY. Direct-acting antivirals for HCV treatment in decompensated liver cirrhosis patients: a systematic review and meta-analysis. J Pers Med. 2022, 12:1517. 10.3390\/jpm12091517","journal-title":"J Pers Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.11.021","article-title":"Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity","volume":"74","author":"Krassenburg LA","year":"2021","unstructured":"Krassenburg LA, Maan R, Ramji A, et al.. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity. J Hepatol. 2021, 74:1053-63. 10.1016\/j.jhep.2020.11.021","journal-title":"J Hepatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.21608\/mjvh.2021.211714","article-title":"Outcomes of direct acting antiviral therapy for treatment of HCV infection in patients with decompensated liver cirrhosis","volume":"6","author":"Bakr D","year":"2021","unstructured":"Bakr D, Hassan I, Abd-Elmaksood E, et al.. Outcomes of direct acting antiviral therapy for treatment of HCV infection in patients with decompensated liver cirrhosis. Med J Viral Hepat. 2021, 6:46-53. 10.21608\/mjvh.2021.211714","journal-title":"Med J Viral Hepat"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2017.11.011","article-title":"Impact of direct acting antiviral drugs in treatment na\u00efve HCV cirrhosis on fibrosis and severity of liver disease: a real life experience from a tertiary care center of North India","volume":"8","author":"Garg G","year":"2018","unstructured":"Garg G, Dixit VK, Shukla SK, et al.. Impact of direct acting antiviral drugs in treatment na\u00efve HCV cirrhosis on fibrosis and severity of liver disease: a real life experience from a tertiary care center of North India. J Clin Exp Hepatol. 2018, 8:241-9. 10.1016\/j.jceh.2017.11.011","journal-title":"J Clin Exp Hepatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.006","article-title":"ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients","volume":"67","author":"Belli LS","year":"2017","unstructured":"Belli LS, Duvoux C, Berenguer M, et al.. ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients. J Hepatol. 2017, 67:585-602. 10.1016\/j.jhep.2017.03.006","journal-title":"J Hepatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.12091","article-title":"Resolution of ascites and hepatic encephalopathy and absence of variceal bleeding in decompensated hepatitis C virus cirrhosis patients","volume":"2","author":"Romano J","year":"2018","unstructured":"Romano J, Sims OT, Richman J, et al.. Resolution of ascites and hepatic encephalopathy and absence of variceal bleeding in decompensated hepatitis C virus cirrhosis patients. JGH Open. 2018, 2:317-21. 10.1002\/jgh3.12091","journal-title":"JGH Open"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.03.031","article-title":"DAA therapy and long-term hepatic function in advanced\/decompensated cirrhosis: real-world experience from HCV-TARGET cohort","volume":"73","author":"Verna EC","year":"2020","unstructured":"Verna EC, Morelli G, Terrault NA, et al.. DAA therapy and long-term hepatic function in advanced\/decompensated cirrhosis: real-world experience from HCV-TARGET cohort. J Hepatol. 2020, 73:540-8. 10.1016\/j.jhep.2020.03.031","journal-title":"J Hepatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v23.i26.4669","article-title":"Impact of hepatitis C oral therapy in portal hypertension","volume":"23","author":"Lib\u00e2nio D","year":"2017","unstructured":"Lib\u00e2nio D, Marinho RT. Impact of hepatitis C oral therapy in portal hypertension. World J Gastroenterol. 2017, 23:4669-74. 10.3748\/wjg.v23.i26.4669","journal-title":"World J Gastroenterol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/v7122968","article-title":"Mechanisms of hepatitis C viral resistance to direct acting antivirals","volume":"7","author":"Ahmed A","year":"2015","unstructured":"Ahmed A, Felmlee DJ. Mechanisms of hepatitis C viral resistance to direct acting antivirals. Viruses. 2015, 7:6716-29. 10.3390\/v7122968","journal-title":"Viruses"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.43079","article-title":"Direct-acting antiviral in the treatment of chronic hepatitis C: bonuses and challenges","volume":"17","author":"Zeng H","year":"2020","unstructured":"Zeng H, Li L, Hou Z, Zhang Y, Tang Z, Liu S. Direct-acting antiviral in the treatment of chronic hepatitis C: bonuses and challenges. Int J Med Sci. 2020, 17:892-902. 10.7150\/ijms.43079","journal-title":"Int J Med Sci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/336738-sustained-virological-response-after-direct-acting-antiviral-therapy-in-hepatitis-c-virus-infected-individuals-with-and-without-decompensated-liver-cirrhosis-a-one-year-follow-up-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T17:28:38Z","timestamp":1740677318000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/336738-sustained-virological-response-after-direct-acting-antiviral-therapy-in-hepatitis-c-virus-infected-individuals-with-and-without-decompensated-liver-cirrhosis-a-one-year-follow-up-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.79766","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,27]]}}}